These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2332773)

  • 1. Failure of 1H nuclear magnetic resonance spectroscopy of blood plasma to detect malignancy.
    Okunieff P; Greenberg MD; Zietman A; Kahn J; Westgate S; Neuringer LJ
    J Clin Oncol; 1990 May; 8(5):906-10. PubMed ID: 2332773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors.
    Okunieff P; Zietman A; Kahn J; Singer S; Neuringer LJ; Levine RA; Evans FE
    N Engl J Med; 1990 Apr; 322(14):953-8. PubMed ID: 2314447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.
    Fossel ET; Carr JM; McDonagh J
    N Engl J Med; 1986 Nov; 315(22):1369-76. PubMed ID: 3022146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [H-NMR spectroscopy of plasma cannot be used for cancer screening].
    Tran Dinh S; Schlumberger M; Gicquel C; Neumann JM; Hervé M; Turpin G; Parmentier C
    Bull Cancer; 1988; 75(8):795-800. PubMed ID: 3179513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR spectroscopy evaluation of plasma "oncolipids" in head and neck cancer.
    Scher RL; Ropka ME; Neal DA; Berr S; Trouard T; Deutsch B; Cantrell RW; Levine PA
    Otolaryngol Head Neck Surg; 1990 Jan; 102(1):34-40. PubMed ID: 2106116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins in malignancy.
    Nabholtz JM; Rossignol A; Farnier M; Gambert P; Tremeaux JC; Friedman S; Guerrin J
    Acta Oncol; 1988; 27(5):479-82. PubMed ID: 3203006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NMR blood test for cancer: current status.
    Fossel ET
    Cancer Cells; 1991 May; 3(5):173-82. PubMed ID: 1654067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer.
    Engan T; Krane J; Klepp O; Kvinnsland S
    N Engl J Med; 1990 Apr; 322(14):949-53. PubMed ID: 2314446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [NMR research on blood plasma for tumor detection--a method for mass screening?].
    Fritzsche H; Sprinz H; Jahn H; Jorke D
    Arch Geschwulstforsch; 1989; 59(2):129-33. PubMed ID: 2719533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer.
    Otvos JD; Jeyarajah EJ; Hayes LW; Freedman DS; Janjan NA; Anderson T
    Clin Chem; 1991 Mar; 37(3):369-76. PubMed ID: 2004443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proton nuclear magnetic resonance spectroscopy of plasma in screening for malignant disease.
    Ono S; Moriyasu F; Nabeshima M; Kajimura K; Yamashita Y; Kimura T; Someda H; Hamato N; Okuma M; Ozawa K
    Cancer; 1992 Sep; 70(6):1638-46. PubMed ID: 1325278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: methodological aspects and clinical relevance.
    Engan T
    Anticancer Res; 1996; 16(3B):1461-71. PubMed ID: 8694514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some factors that influence the plasma lipoprotein 1H NMR spectra of normal and cancer patients: an oncolipid test?
    Lim HM; Price TB; Marsh JC; Rainey PM; Gore JC; Armitage IM
    Yale J Biol Med; 1991; 64(1):63-77. PubMed ID: 1897263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma.
    Mims MP; Morrisett JD; Mattioli CA; Gotto AM
    N Engl J Med; 1989 Jun; 320(22):1452-7. PubMed ID: 2716796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.
    Dowd TL; Kaplan BA; Gupta RK; Aisen P
    Magn Reson Med; 1987 Oct; 5(4):395-7. PubMed ID: 3683172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions.
    Fossel ET; Hall FM; McDonagh J
    Breast Cancer Res Treat; 1991 May; 18(2):99-110. PubMed ID: 1912613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy.
    Wilding P; Senior MB; Inubushi T; Ludwick ML
    Clin Chem; 1988 Mar; 34(3):505-11. PubMed ID: 3349601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton NMR spectroscopy of plasma lipoproteins: a marker of the immune function in cancer disease?
    Leray G; de Certaines JD
    Anticancer Res; 1994; 14(5A):1839-51. PubMed ID: 7847817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of tumours with nuclear magnetic resonance spectroscopy of plasma.
    Berger S; Pflüger KH; Etzel WA; Fischer J
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):535-43. PubMed ID: 2703007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostatic tumors. Detection by proton nuclear magnetic resonance spectroscopy of plasma lipoproteins].
    Nabholtz JM; Tremeaux JC; Rossignol A; Farnier M; Gambert P; Briet S; Guerrin J
    J Urol (Paris); 1989; 95(4):209-12. PubMed ID: 2477463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.